首页> 外文期刊>Neoplasma: Journal of Experimental and Clinical Oncology >Secondary malignancies after hematopoietic stem cell transplantation.
【24h】

Secondary malignancies after hematopoietic stem cell transplantation.

机译:造血干细胞移植后的继发性恶性肿瘤。

获取原文
获取原文并翻译 | 示例
           

摘要

Hematopoietic stem cell transplantation (HSCT) offers patients with malignant and nonmalignant diseases the oportunity to pursue life-prolonging therapy. The number of survivors after successful HSCT is continually increasing. However, HSCT can induce tissue and organ damage that occurs not only "on treatment" , but long after completing therapy. Secondary malignancies belong to serious late complications after HSCT. A significant association of certain risk factors with increased likelihood of secondary malignancies after HSCT has been published over the last ten years. Better knowledge of pathogenesis of these complications, their early identification and treatment may contribute to better health outcomes of allogeneic and autologous hematopoietic stem cell transplantation recipients. We review here the incidence and risk factors of secondary malignancies after hematopoietic stem cell transplantation. Keywords: hematopoietic stem cell transplantation, late complications, secondary malignancies.
机译:造血干细胞移植(HSCT)为患有恶性和非恶性疾病的患者提供了延长生命的疗法的机会。成功进行HSCT后的幸存者人数不断增加。但是,HSCT不仅会引起组织和器官损伤,而且不仅在“治疗”期间发生,而且会在完成治疗后很长时间发生。继发性恶性肿瘤是HSCT术后严重的晚期并发症。在过去的十年中,HSCT后某些危险因素与继发性恶性肿瘤发生的可能性显着相关。更好地了解这些并发症的发病机理,及早发现和治疗可能有助于异体和自体造血干细胞移植接受者获得更好的健康结果。我们在这里回顾了造血干细胞移植后继发性恶性肿瘤的发生率和危险因素。关键词:造血干细胞移植,晚期并发症,继发性恶性肿瘤。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号